Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IFN beta 1a TIW · 1 trial · 1 indication
A single T2 lesion was defined as an area of increased signal on a given 3-millimeters axial image that was not referable to normally hyperintense structures. New T2 lesions were those that appear in areas where on the previous scan no abnormality was detected. All T2 lesions were detected by an MRI scan.
| Arm | Type | Description |
|---|---|---|
| IFN beta 1a 44 mcg TIW + curcumin (BCM95) | EXPERIMENTAL | - |
| IFN beta 1a 44 mcg TIW + placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IFN beta 1a 44 mcg TIW | DRUG | Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months. |
| Curcumin | DRUG | Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months. |
| Placebo | DRUG | Subjects received placebo matched to curcumin orally twice a day for 24 months. |
Inclusion Criteria: * Subjects with early diagnosis (no more than 3 years) of Relapsing Multiple Sclerosis according to the revised McDonald Criteria (2010) * Subjects currently in treatment with IFN beta-1a 44 mcg TIW, having received this treatment a minimum of 6 months and for not longer than 12...
Top 17 of 21 competitors